Compare Marathon Digital Holdings Inc (MARA) vs Moderna, Inc. (MRNA) Price & Performance

Marathon Digital Holdings (MARA) trades at $9.65, down 6.85% in the last session, reflecting ongoing volatility. The stock shows mixed signals with bearish technical indicators but positive analyst sentiment. Recent earnings have consistently missed expectations, with Q2 2026 EPS of -$1.60 versus expected $0.17. Despite negative profitability metrics, the company maintains strong analyst coverage with a consensus price target of $13.25, suggesting 37% upside potential from current levels.

MARA presents a high-risk opportunity with significant divergence between fundamental performance and market expectations. While valuation ratios appear attractive (P/E 3.37, EV/EBITDA 3.31), persistent negative earnings and cash flow challenges create substantial execution risk. The stock's performance remains heavily dependent on broader market sentiment and the company's ability to improve operational efficiency amid competitive pressures.

Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.

While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.